MacroGenics. has been granted a patent for chimeric 4D5 antibodies that specifically target HER2/neu with reduced glycosylation. The patent covers methods for using these antibodies in diagnosing and treating various diseases, including HER2/neu-expressing cancers, through intravenous administration. GlobalData’s report on MacroGenics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on MacroGenics, Personalized cancer vaccines was a key innovation area identified from patents. MacroGenics's grant share as of June 2024 was 40%. Grant share is based on the ratio of number of grants to total number of patents.
Antibodies targeting her2/neu for cancer treatment
The patent US12024569B2 outlines a method for treating HER2/neu-expressing cancers through the administration of a specific antibody. This antibody is characterized by an immunoglobulin light chain and an immunoglobulin heavy chain, with defined amino acid sequences (SEQ ID NO: 2 and SEQ ID NO: 11, respectively). The treatment is delivered via intravenous infusion, targeting patients diagnosed with various types of HER2/neu-expressing cancers, including breast, prostate, and ovarian cancers. The claims also allow for the simultaneous or sequential administration of a second therapeutic agent, which can include anti-angiogenic, anti-neoplastic, chemotherapeutic, or cytotoxic agents, with specific examples such as cisplatin, doxorubicin, or paclitaxel.
Further claims detail the formulation of the pharmaceutical composition, which includes the antibody and a pharmaceutically acceptable carrier or excipient, also administered intravenously. The method emphasizes the importance of timing, stipulating that the second therapeutic agent should be administered no more than 96 hours apart from the antibody. Additional options for the second therapeutic agent include anti-mitotic agents, hormone therapy agents, and aromatase inhibitors. The patent thus provides a comprehensive approach to treating HER2/neu-expressing cancers, highlighting both the specific antibody composition and the potential for combination therapies to enhance treatment efficacy.
To know more about GlobalData’s detailed insights on MacroGenics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
